A Breakthrough Therapy designation granted by the @FDA will help advance a potential treatment option that could be meaningful for previously treated patients with a certain form of advanced #pancreaticcancer#. Learn more:

Pancreatic cancer was long considered one of medicine’s deadliest diagnoses. But today, the FDA approved @RevMedicines' Daraxonrasib - a new treatment that has in trials nearly doubled how long patients survive compared to standard chemotherapy. Daraxonrasib works by targeting a molecule, KRAS, that until now was considered undruggable. The story is a reflection of biotech at its best - pioneering what was once believed impossible, persevering through booms and busts, bringing together enabling research, academic labs, and industry to create breakthroughs for patients and their families.  The FDA deserves our commendation for approving this life-changing treatment with the urgency it demanded, and for moving quickly to allow patients to begin accessing it even before formal approval. Who can say how many lives have been extended - how many more birthdays and weddings and anniversaries will be celebrated - thanks to this wonder of science. Here’s to continuing the momentum on revolutionary new treatments for cancer.

Revolution Medicines’s pancreatic cancer drug won the backing of a key EU advisory panel, the company said in a statement Thursday, moving the life-extending medicine closer to reaching patients in the 27-nation bloc

Revolution Medicines $RVMD pancreatic cancer pill has officially been FDA approved as of 8/26 Cost? $39,800/month for patients suffering from late stage cancer The stock is +167% YTD

$TNGX This Pancreatic Cancer Gem is giving another technical Setup "92% Response Rate in pancreatic Cancer and Runup into Phase 3 Data" We stopped out last time. For In Depth Analysis check @tenet_research Target remains 30/34+ on this triple bottom gap bounce @Pharmdca